Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BioLASCO Taiwan Co., Ltd. (6662:TWSE), powered by AI.
BioLASCO Taiwan Co., Ltd. is currently trading at $29.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for BioLASCO Taiwan Co., Ltd. on Alpha Lenz.
View BioLASCO Taiwan Co., Ltd.'s valuation metrics on Alpha Lenz.
“BioLASCO Taiwan Co., Ltd.'s ROE is 9.4%. Explore profitability and growth together.”
Ask for details →BioLASCO Taiwan Co., Ltd. is a biotechnology firm specializing in the breeding, production, and supply of Specific Pathogen Free (SPF) laboratory animals, such as rats and mice, to support biomedical research and pharmaceutical development. The company's offerings encompass a comprehensive portfolio of outbreed stocks, inbred strains, immune-deficient models, and specialized animal models—critical tools for laboratories in Taiwan and internationally. Beyond laboratory animals, BioLASCO also provides a broad suite of laboratory equipment and support services, including diagnostic kits, endotoxin detection, animal facility systems, and research instrumentation tailored for preclinical studies. Notably, the company partners with leading international organizations and holds full accreditation from AAALAC International, reflecting its commitment to high standards in animal welfare and research quality. By enabling reliable and reproducible animal-based studies, BioLASCO plays a pivotal role in advancing life sciences and medical innovation across multiple sectors, from academic research to pharmaceutical enterprise, thus serving as a vital supplier within the global healthcare and biotechnology industry.
“BioLASCO Taiwan Co., Ltd.'s ROE is 9.4%. Explore profitability and growth together.”
Ask for details →BioLASCO Taiwan Co., Ltd. (ticker: 6662) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 91 employees.
The current price is 29.95 with a P/E ratio of -x and P/B of -x.
ROE is 9.35% and operating margin is 18.32%. Annual revenue is $263M.